tiprankstipranks
Trending News
More News >

Taysha Gene Therapies price target raised to $9 from $7 at Chardan

Chardan raised the firm’s price target on Taysha Gene Therapies (TSHA) to $9 from $7 and keeps a Buy rating on the shares. After Taysha disclosed details of its FDA-aligned pivotal Part B trial design for its Rett program, the firm said it sees the latest developments as “a favorable outcome for Taysha” and updated its model to increase its view of the Rett odds of success to 45% from 35%, the analyst tells investors.

Confident Investing Starts Here:

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue

1